Hemoconcentrators are medical devices used by healthcare professionals or perfusionist (health care professional who operates heart-lung bypass equipment), to concentrate red blood cells and remove excess fluid from the bloodstream during surgery. During surgery, the entire blood volume of the patient passes through the hemoconcentrator.
Hemoconcentrators is gaining significant traction in cardio bypass surgery, as it reduces the need for homologous blood and blood products by providing patients with their own concentrated whole blood. It maintains the desired hematocrit level for oxygen transport to tissues; it decreases the risk of post-operative bleeding through the retention of platelets and plasma coagulation proteins; it maintains oncotic pressure by retaining plasma proteins while quickly and gently removing excess plasma water; and minimizes the need for diuretic use, which may be contraindicated for some patients.
Market Dynamics
Hemoconcentrators are widely used as gold standard for removal of fluid during cardio bypass surgery. Cardiovascular diseases are the most common and life threatening diseases.
For instance, according to the data published by Centers of Disease Control and Prevention (CDC), heart diseases are the leading cause of death in the U.S. Annually around 630,000 people in the U.S. die from heart diseases, which is around 1 in every 4 deaths. According to the same source in the U.S., one patient suffers from heart attack in every 40 seconds. Each minute, more than one person in the U.S. dies from heart disease.
Such high prevalence of cardiovascular diseases in key regions such as North America and Asia-Pacific is expected to be a major factor propelling demand for hemoconcentrators and drive global adult and pediatric hemoconcentrators market growth over the forecast period.
Furthermore, key players in the market are adopting strategic partnership and collaboration activities for expanding its presence in the market. For instance, in 2016, MEDIVATORS Inc. (a Cantel Medical Corporation company), a manufacturer of Hemocor HPH family hemoconcentrators expanded its direct sales operations in Canada by acquiring endoscope reprocessing business assets from its Canadian distributor, Vantage Endoscopy, Inc., a subsidiary of Diploma Canada Holdings Ltd.
Key features of the study
Market Segmentation
Table of Contents
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients